

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Withdrawn, Currently Amended): A method for producing

~~an oral pharmaceutical form with immediate disintegration and active ingredient release even in the mouth~~

a pharmaceutical composition that when placed in the mouth immediately disintegrates releasing active ingredient (a) comprising:

~~wherein said powder when placed in the mouth disintegrates within 30 seconds and releases active ingredient (a), comprising~~

vigorously mixing

(a) an anionic active pharmaceutical ingredient with

(b) a copolymer consisting of free-radical polymerized C₁ to C₄ esters of acrylic or methacrylic acid and further (meth)acrylate monomers which have functional tertiary amino groups, and

(c) 5 to 50% by weight, based on (b), of a C₁₂ to C₂₂ carboxylic acid

in a melt,

solidifying the mixture, and

grinding to an active ingredient-containing powder with an average particle size of 200 µm or less,

incorporating the powder into a water-soluble matrix of at least one pharmaceutically acceptable excipient ~~pharmaceutically customary excipients,~~

with the proviso that not more than 3% by weight, based on the copolymer (b), of emulsifiers having an HLB of at least 14 may be present.

Claim 2 (Withdrawn, Currently Amended): The method as claimed in [[c]]Claim 1, wherein a twin-screw extruder is employed for the purpose of vigorous mixing in the melt.

Claim 3 (Withdrawn, Currently Amended): The method as claimed in [[c]]Claim 1, wherein extrusion takes place at temperatures in the range from 80 to 200°C

Claim 4 (Withdrawn): The method as claimed in Claim 1, wherein the incorporation of the powder into the water-soluble matrix takes place by compression, casting, granulation or freeze drying.

Claim 5 (Currently Amended): ~~An active ingredient containing~~ A powder with an average particle size of 200 µm or less, comprising:

- (a) an anionic active pharmaceutical ingredient ~~which is in the form of a solid solution and is incorporated into~~
- (b) a copolymer which consists of free-radical polymerized C₁ to C₄ esters of acrylic or methacrylic acid and further (meth)acrylate monomers which have functional tertiary amino groups, and
- (c) 5 to 50% by weight, based on (b), of a C₁₂ to C₂₂ carboxylic acid [[,]]
- (d) with the proviso that less than 3% by weight[[,]] based on the copolymer of an ~~or no~~ emulsifier having an HLB of at least 14 is present,
wherein said powder when placed in the mouth immediately disintegrates and releases active ingredient (a).

Claim 6 (Currently Amended): ~~The active ingredient containing powder as claimed in claim of Claim 5, wherein (a) comprises an anionic analgesic, or an anionic antirheumatic, or an anionic antibiotic is present as anionic active ingredient (a).~~

Claim 7 (Currently Amended): ~~An active ingredient containing powder as claimed in claim 5~~

The powder of Claim 5, wherein the anionic active pharmaceutical ingredient (a) is at least one selected from the group consisting of acamprosate, aceclofenac, acemetacin, acetylcysteine, acetylsalicylic acid, acetyltyrosine, acipimox, acitretin, alanine, alendronic acid, amethopterin, amino acids, amoxicillin, ampicillin, ascorbic acid, atorvastatin, azidocillin, aztreonam, bacampicillin, baclofen, benazepril, bendamustine, benzylpenicillin, bezafibrate, biotin, bornaprine, bumetanide, cabastine, canrenoic acid, carbamoylphenoxyacetic acid, carbidopa, carbimazole, carbocysteine, carisoprodol, cefaclor, cefadroxil, cefalexin, cefazolin, cefepime, cefetamet, cefixime, cefotaxime, cefotiam, cefoxitin, cefpodoxime, ceftazidime, ceftibuten, ceftriaxone, cefuroxime, cetirizine, chenodeoxycholic acid, chlorambucil, cidofovir, cilastatin, cilazapril, cinoxacin, ciprofloxacin, cisatracurium besilate, clavulanic acid, clodronic acid, clorazepate, cromoglicic acid, desmeninol, diclofenac, dicloxacillin, enoxacin, eprosartan, etacrynic acid, etidronic acid, etofylline, etomidate, felbinac, felodipine, fenofibrate, fexofenadine, flavoxate, fleroxacin, flucloxacillin, flufenamic acid, flumazenil, flupirtine, flurbiprofen, fluvastatin, fosfomycin, fosinopril, furosemide, fusidic acid, gabapentine, gemfibrozil, ibandronic acid, ibuprofen, iloprost, imidapril, imipenem, indomethacin, irinotecan, isradipine, ketoprofen, lercanidipine, levodopa, levofloxacin, liothyronine, lipoic acid, lisinopril, lodoxamide, lomefloxacin, lonazolac, loracarbef, loratadine, lovastatin, mefenamic acid, meropenem, mesalazine, metamizole, methotrexate, methyl dopa, mezlocillin, moexipril, montelukast,

moxifloxacin, mupirocin, naproxen, natamycin, nateglinide, nedocromil, nicotinic acid, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, norfloxacin, ofloxacin, olsalazine, orotic acid, oxacillin, pamidronic acid, pangamic acid, penicillamine, phenoxymethylpenicillin, pentosan polysulfate, perindopril, pethidine, pipemidic acid, piperacillin, pirenoxine, piretanide, probenecid, proglumide, propicillin, prostaglandins, quinapril, quinaprilate, ramipril, repaglinide, reserpine, risedronic acid, salicylic acid, sulfasalazine, spirapril, sulbactam, sulfasalazine, sultamicillin, tazarotene, tazobactam, telmisartan, tiagabine, tiaprofenic acid, tilidine, tiludronic acid, trandolapril, tranexamic acid, valproic acid, vigabatrine, vincamine, vinpocetine, zanamivir, zoledronic acid, zopiclone, salts thereof, and isomers thereof.

Claims 8-11 (Cancelled)

Claim 12 (New): The powder of Claim 5, wherein said anionic active pharmaceutical ingredient (a) has been incorporated into said copolymer (b).

Claim 13 (New): The powder of Claim 5, wherein copolymer (b) comprises methyl methacrylate, butyl methacrylate, and dimethylaminoethyl methacrylate.

Claim 14 (New): The powder of Claim 5, wherein carboxylic acid (c) is at least one of lauric acid, myristic acid, palmitic acid, or stearic acid.

Claim 15 (New): The powder of Claim 5 that contains no emulsifier having an HLB (hydrophilic/lipophilic balance) of 14 or more.

Claim 16 (New): The powder of Claim 5 that contains 1-3% emulsifier having an HLB (hydrophilic/lipophilic balance) of 14 or more.

Claim 17 (New): The powder of Claim 5 that contains 1-2% emulsifier having an HLB (hydrophilic/lipophilic balance) of 14 or more.

Claim 18 (New): The powder of Claim 5, which has a bitterness value determined by DAB 1999 method 2.8.N8 below 1,000 for at least 30 seconds after release of the active ingredient (a).

Claim 19 (New): A pharmaceutical composition comprising the powder of Claim 5 and at least one pharmaceutically acceptable excipient.

Claim 20 (New): The pharmaceutical composition of Claim 19, wherein said at least one excipient is a release agent having an HLB between 3 and 8.

Claim 21 (New): The pharmaceutical composition of Claim 19, wherein said at least one excipient is a plasticizer having a molecular weight ranging between 100 and 20,000 and which comprises at least one hydrophilic group.

Claim 22 (New): The pharmaceutical composition of Claim 19 in the form of a compressed tablet, suckable tablet, freeze-dried tablet, cast tablet, pastilles, sachet, chewable tablet, powder for reconstitution, lozenge and/or liquid-filled lozenge.

Claim 23 (New): The powder of Claim 5 which is produced by:

vigorously mixing

- (a) an anionic active pharmaceutical ingredient with
- (b) a copolymer consisting of free-radical polymerized C₁ to C₄ esters of acrylic or methacrylic acid and further (meth)acrylate monomers which have functional tertiary amino groups, and
- (c) 5 to 50% by weight, based on (b), of a C₁₂ to C₂₂ carboxylic acid

in a melt,

solidifying the mixture, and

grinding to an active ingredient-containing powder with an average particle size of 200 μm or less,

incorporating the powder into a water-soluble matrix of at least one pharmaceutically acceptable excipient.